|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-20.59/-10.40
|
企业价值
218.03M
|
资产负债 |
每股账面净值
-5.91
|
现金流量 |
现金流量率
--
|
损益表 |
收益
83.81M
|
每股收益
2.22
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases. |